Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Blood Cancer Discov. 2020 Sep;1(2):198–213. doi: 10.1158/2643-3230.BCD-19-0077

Figure 7.

Figure 7.

Treatment of CD36 blocking antibody delays leukemia engraftment in NSG murine model. A, NSG mice were engrafted with MOLM-13 cells for 7 days and then treated with CD36 antibody (CD36Ab) or IgG control. Representative flow cytometry results showing the engraftment of BM, PB, and spleen, quantification of engraftment in BM, PB, and spleen. B, Spleens collected from mice engrafted with MOLM-13 and treated with IgG and CD36 antibody and comparison of spleen weight between IgG group and CD36 antibody group. C, Survival data from mice engrafted with MOLM-13 and treated with IgG and CD36 antibody. D, Histology staining of Ki67 antibody on spleen and liver sections from mice engrafted with MOLM-13 and treated with IgG and CD36 antibody. Quantification analysis and representative staining of tissue sections obtained from the different organs. E, Histology staining of human CD45 antibody on spleen and liver sections from mice engrafted with MOLM-13 and treated with IgG and CD36 antibody. Quantification analysis and representative staining of tissue sections obtained from the different organs. The differences between the groups were analyzed using unpaired t tests (****, P < 0.0001; **, P < 0.01; *, P < 0.05).